Therapy Detail

Therapy Name MEHD7945A + Cobimetinib
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cobimetinib Cotellic GDC-0973 MEK inhibitor (Pan) 20 MEK1 Inhibitor 20 MEK2 Inhibitor 18 Cotellic (cobimetinib) is an allosteric inhibitor of MEK1/2, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation (PMID: 22084396, PMID: 27956260). Cotellic (cobimetinib) is FDA approved for melanoma patients with BRAF V600E or V600K, in combination with Zelboraf (vemurafenib) (
Duligotuzumab MEHD7945A EGFR Antibody 27 HER3 (ERBB3) Antibody 13 Duligotuzumab (MEHD7945A) is a two-in-one antibody that inhibits both ERBB3 (HER3) and EGFR signaling, resulting in greater efficacy than monospecific HER antibodies against multiple tumor models (PMID: 22014573).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS mutant Advanced Solid Tumor no benefit MEHD7945A + Cobimetinib Phase I Actionable In a Phase I trial, Duligotuzumab (MEHD7945A) and Cotellic (cobimetinib) combination therapy demonstrated limited safety and efficacy, with stable disease as best response in 41% (9/22) of patients with KRAS-mutant solid tumors (PMID: 28592615; NCT01986166). 28592615
Clinical Trial Phase Therapies Title Recruitment Status
NCT01986166 Phase I MEHD7945A + Cobimetinib A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS Completed